In a report released on July 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,500.00. The company’s shares closed yesterday at p1,418.00.

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.